IL261420A - Methods for treating clients with hyperlipidemia by adding a pcsk9 blocker in combination with an angpt3 blocker - Google Patents

Methods for treating clients with hyperlipidemia by adding a pcsk9 blocker in combination with an angpt3 blocker

Info

Publication number
IL261420A
IL261420A IL261420A IL26142018A IL261420A IL 261420 A IL261420 A IL 261420A IL 261420 A IL261420 A IL 261420A IL 26142018 A IL26142018 A IL 26142018A IL 261420 A IL261420 A IL 261420A
Authority
IL
Israel
Prior art keywords
inhibitor
hyperlipidemia
administering
methods
combination
Prior art date
Application number
IL261420A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL261420A publication Critical patent/IL261420A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL261420A 2016-03-03 2018-08-28 Methods for treating clients with hyperlipidemia by adding a pcsk9 blocker in combination with an angpt3 blocker IL261420A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302907P 2016-03-03 2016-03-03
PCT/US2017/020221 WO2017151783A1 (en) 2016-03-03 2017-03-01 Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor

Publications (1)

Publication Number Publication Date
IL261420A true IL261420A (en) 2018-10-31

Family

ID=58361088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261420A IL261420A (en) 2016-03-03 2018-08-28 Methods for treating clients with hyperlipidemia by adding a pcsk9 blocker in combination with an angpt3 blocker

Country Status (13)

Country Link
US (2) US20170253666A1 (enExample)
EP (1) EP3423157A1 (enExample)
JP (3) JP7541810B2 (enExample)
KR (1) KR102456731B1 (enExample)
CN (1) CN109069868B (enExample)
AU (1) AU2017227713B2 (enExample)
CA (1) CA3016764A1 (enExample)
EA (1) EA201891979A1 (enExample)
IL (1) IL261420A (enExample)
MA (1) MA43734A (enExample)
MX (1) MX2018010401A (enExample)
WO (1) WO2017151783A1 (enExample)
ZA (1) ZA201805403B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN109069868B (zh) 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
JP7201437B2 (ja) * 2016-04-28 2023-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 家族性高コレステロール血症を有する患者を処置するための方法
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
CA3188213A1 (en) * 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
WO2025185644A1 (zh) * 2024-03-05 2025-09-12 江苏恒瑞医药股份有限公司 抗angptl3抗体治疗高血脂症的用途及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
EP1151092B1 (en) 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ATE357216T1 (de) 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
KR101012904B1 (ko) 2001-11-16 2011-02-08 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는조성물 및 이를 사용하는 방법
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
HUE033960T2 (en) 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
DK2398476T3 (en) 2009-02-23 2018-04-16 Nanorx Inc POLICOSANOL NANOPARTICLES
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
ES2677969T3 (es) 2010-01-08 2018-08-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión tipo angiopoyetina 3
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
KR102232287B1 (ko) 2011-06-21 2021-03-29 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
MX2015004668A (es) 2012-10-25 2015-07-23 Medimmune Llc Formulacion estable de anticuerpos de baja viscosidad.
US20160002315A1 (en) 2013-03-14 2016-01-07 Uab Research Foundation Apolipoprotein mimetics and uses thereof
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
CA2914721A1 (en) 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
WO2015100394A1 (en) 2013-12-24 2015-07-02 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP3845547A1 (en) 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression
CA2955294A1 (en) * 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
EP3753575A1 (en) 2014-07-16 2020-12-23 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9
US10071139B2 (en) 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PT3416684T (pt) 2016-02-17 2023-07-04 Regeneron Pharma Métodos para tratamento ou prevenção da aterosclerose por administração de um inibidor da angptl3
CN109069868B (zh) 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
AU2017248356A1 (en) 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor
JP7201437B2 (ja) 2016-04-28 2023-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 家族性高コレステロール血症を有する患者を処置するための方法
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US20200369760A1 (en) 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CA3188213A1 (en) 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor

Also Published As

Publication number Publication date
ZA201805403B (en) 2019-08-28
CN109069868A (zh) 2018-12-21
MX2018010401A (es) 2019-03-06
EA201891979A1 (ru) 2019-01-31
US20200199253A1 (en) 2020-06-25
US20170253666A1 (en) 2017-09-07
KR102456731B1 (ko) 2022-10-24
AU2017227713A1 (en) 2018-09-13
CA3016764A1 (en) 2017-09-08
EP3423157A1 (en) 2019-01-09
KR20180118181A (ko) 2018-10-30
AU2017227713B2 (en) 2022-12-22
JP7541810B2 (ja) 2024-08-29
CN109069868B (zh) 2023-06-06
JP2022078306A (ja) 2022-05-24
MA43734A (fr) 2018-11-28
JP2019512472A (ja) 2019-05-16
JP2024059787A (ja) 2024-05-01
WO2017151783A1 (en) 2017-09-08
US12281173B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
IL261420A (en) Methods for treating clients with hyperlipidemia by adding a pcsk9 blocker in combination with an angpt3 blocker
IL262130A (en) Methods for treating excess fat in the blood using angptl8 inhibitor and angptl3 inhibitor
IL271212A (en) Methods for treating excess blood fat in diabetic patients by administering a pcsk9 inhibitor
ZA201806557B (en) Methods for treating patients with familial hypercholesterolemia
SG10202005298RA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
ZA201701578B (en) Combination therapy for treating a paramyxovirus
GB201522398D0 (en) Device for photodynamic therapy
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
SG11201610333VA (en) Combination therapy with glutaminase inhibitors
PL3169353T3 (pl) SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
SI3371165T1 (sl) Zaviralec BTK za uporabo pri zdravljenju raka
IL242021B (en) Combination therapy containing a tor kinase inhibitor and a cytidine analog for cancer treatment
PL3463436T3 (pl) Szczepionka w połączeniu z inhibitorem immunologicznego punktu kontrolnego do stosowania w leczeniu nowotworów
PL3157548T3 (pl) Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
PL3390448T3 (pl) Terapia dopęcherzowa raka pęcherza moczowego
GB201821147D0 (en) Mirna for use in therapy
HK1261754A1 (en) Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
PT3167881T (pt) Etamsilato administrado localmente como medicamento
IL256336A (en) Device for laser and/or LED treatment
HK40027567A (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
HK1262072A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
HK1232804A1 (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
IL250080B (en) Treatment methods for patients with familial heterozygous hypercholesterolemia
GB201611016D0 (en) Therapeutic treatments
GB201611017D0 (en) Therapeutic treatments